Cargando…
(90)Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma
Finding improved therapeutic strategies against T-cell Non-Hodgkin’s Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumor-targeting alkylphosphocholine (NM600) radiolabeled with (86)Y for positron emission tomography (PET) imaging and (90)Y for targe...
Autores principales: | Hernandez, Reinier, Walker, Kirsti L., Grudzinski, Joseph J., Aluicio-Sarduy, Eduardo, Patel, Ravi, Zahm, Christopher D., Pinchuk, Anatoly N., Massey, Christopher F., Bitton, Ariana N., Brown, Ryan J., Sondel, Paul M., Morris, Zachary S., Engle, Jonathan W., Capitini, Christian M., Weichert, Jamey P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391402/ https://www.ncbi.nlm.nih.gov/pubmed/30820474 http://dx.doi.org/10.1038/s42003-019-0327-4 |
Ejemplares similares
-
(177)Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
por: Hernandez, Reinier, et al.
Publicado: (2020) -
Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
por: Potluri, Hemanth K, et al.
Publicado: (2022) -
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting
por: Magee, Kara, et al.
Publicado: (2021) -
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
por: Kerr, Caroline P., et al.
Publicado: (2022) -
Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy
por: Jagodinsky, Justin C., et al.
Publicado: (2021)